tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Allogene Therapeutics price target lowered to $9 from $12 at Baird

Baird analyst Jack Allen lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $12 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its ALPHA3 Lymphodepletion decision and ALLO-329 data was pushed to 1H26.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1